{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:26:00Z","timestamp":1791728760382,"version":"4.3.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1344,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR-CM patients compared with heart failure (HF) patients, in Denmark, Finland, Norway, and Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Data from nationwide healthcare registers in the four countries were used. ATTR-CM patients were defined as individuals diagnosed with amyloidosis and cardiomyopathy or HF between 2008 and 2018. Patients in the ATTR-CM cohort were matched to patients with HF but without ATTR-CM diagnosis. Resource use included number of visits to specialty outpatient and inpatient hospital care. A total of 1831 ATTR-CM and 1831 HF patients were included in the analysis. The mean number of hospital-based healthcare contacts increased in both the ATTR-CM and HF cohort during 3 years pre-diagnosis and was consistently higher for the ATTR-CM cohort compared with the HF cohort, with 6.1 [CI: 5.9\u20136.3] vs. 3.2 [CI: 3.1\u20133.3] outpatient visits and 1.03 [CI: 0.96\u20131.1] vs. 0.7 [CI: 0.7\u20130.8] hospitalizations. In the first year following diagnosis, patients with ATTR-CM continued to visit outpatient care (10.2 [CI: 10.1, 10.4] vs. 5.7 [CI: 5.6, 5.9]) and were admitted to hospital more frequently (3.3 [CI: 3.2, 3.4] vs. 2.5 [CI: 2.5, 2.6]) than HF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy imposes a high burden on healthcare systems with twice as many outpatient specialist visits and 50% more hospitalizations in the year after diagnosis compared with HF patients without ATTR-CM. Studies to investigate if earlier diagnosis and treatment of ATTR-CM may lower resource use are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13913","type":"journal-article","created":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:40:32Z","timestamp":1648867232000},"page":"1636-1642","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Healthcare Resource Use of Patients with Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-6600","authenticated-orcid":false,"given":"Rosa","family":"Lauppe","sequence":"first","affiliation":[{"name":"Quantify Research AB , Stockholm, 112 21 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Liseth Hansen","sequence":"additional","affiliation":[{"name":"Quantify Research AB , Stockholm, 112 21 ,","place":["Sweden"]},{"name":"Institute of Health and Society, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fornwall","sequence":"additional","affiliation":[{"name":"Quantify Research AB , Stockholm, 112 21 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Johansson","sequence":"additional","affiliation":[{"name":"Pfizer AB , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Rozenbaum","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , Capelle aan den IJssel ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Mette","family":"Strand","sequence":"additional","affiliation":[{"name":"Pfizer Denmark ApS , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Vakevainen","sequence":"additional","affiliation":[{"name":"Pfizer Oy , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kuusisto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Research, Kuopio University Hospital and University of Eastern Finland , Kuopio ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Gude","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gustav","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Clinical Sciences, Lund University and Sk\u00e5ne University Hospital , Lund ,","place":["Sweden"]},{"name":"The Wallenberg Laboratory\/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"2026012114231862900_ehf213913-bib-0001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-020-00738-8","article-title":"Advances in the treatment of cardiac amyloidosis","volume":"21","author":"Macedo","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2026012114231862900_ehf213913-bib-0002","first-page":"709","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC: Heart Fail"},{"key":"2026012114231862900_ehf213913-bib-0003","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","article-title":"Diagnosis of transthyretin amyloid cardiomyopathy","volume":"9","author":"Hafeez","year":"2020","journal-title":"Cardiol Ther"},{"key":"2026012114231862900_ehf213913-bib-0004","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","article-title":"Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups","volume":"16","author":"Rintell","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2026012114231862900_ehf213913-bib-0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114231862900_ehf213913-bib-0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"key":"2026012114231862900_ehf213913-bib-0007","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026012114231862900_ehf213913-bib-0008","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001755","article-title":"Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden","volume":"8","author":"Lauppe","year":"2021","journal-title":"Open Heart"},{"key":"2026012114231862900_ehf213913-bib-0009","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2217\/cer-2021-0071","article-title":"Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2026012114231862900_ehf213913-bib-0010","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114231862900_ehf213913-bib-0011","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","article-title":"Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan","volume":"8","author":"Winburn","year":"2019","journal-title":"Cardiol Ther"},{"key":"2026012114231862900_ehf213913-bib-0012","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaccao.2021.05.004","article-title":"Two decades of cardiac amyloidosis: a Danish nationwide study","volume":"3","author":"Westin","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026012114231862900_ehf213913-bib-0013","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.3131","article-title":"Epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) in France, a study based on the systeme national des donnees de sante (SNDS) the French nationwide claims database","volume":"42","author":"Damy","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114231862900_ehf213913-bib-0014","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.19365.2","article-title":"Humanistic burden and economic impact of heart failure ? A systematic review of the literature [version 2; peer review: 1 approved, 1 approved with reservations]","volume":"8","author":"Giles","year":"2020","journal-title":"F1000Research"},{"key":"2026012114231862900_ehf213913-bib-0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004\u20132016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2026012114231862900_ehf213913-bib-0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-017-9661-0","article-title":"Systematic review of economic burden of heart failure","volume":"23","author":"Shafie","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2026012114231862900_ehf213913-bib-0017","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/13696998.2020.1789866","article-title":"Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark","volume":"23","author":"Pilgaard","year":"2020","journal-title":"J Med Econ"},{"key":"2026012114231862900_ehf213913-bib-0018","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40120-020-00194-4","article-title":"The clinical and economic burden of newly diagnosed hereditary transthyretin (ATTRv) amyloidosis: a retrospective analysis of claims data","volume":"9","author":"Reddy","year":"2020","journal-title":"Neurol Ther"},{"key":"2026012114231862900_ehf213913-bib-0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","article-title":"Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers","volume":"7","author":"Stewart","year":"2018","journal-title":"Neurol Ther"},{"key":"2026012114231862900_ehf213913-bib-0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"2026012114231862900_ehf213913-bib-0021","volume-title":"R: A Language and Environment for Statistical Computing","author":"Team RC","year":"2021"},{"key":"2026012114231862900_ehf213913-bib-0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13913","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/3\/1636\/65668757\/eschf_9_3_1636.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/3\/1636\/65668757\/eschf_9_3_1636.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:29:09Z","timestamp":1769023749000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/3\/1636\/8362411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,1]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13913","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"2021-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}